0001213900-23-059044.txt : 20230724 0001213900-23-059044.hdr.sgml : 20230724 20230724090259 ACCESSION NUMBER: 0001213900-23-059044 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 15 CONFORMED PERIOD OF REPORT: 20230724 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Material Modifications to Rights of Security Holders ITEM INFORMATION: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20230724 DATE AS OF CHANGE: 20230724 FILER: COMPANY DATA: COMPANY CONFORMED NAME: ABVC BIOPHARMA, INC. CENTRAL INDEX KEY: 0001173313 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 260014658 STATE OF INCORPORATION: NV FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-40700 FILM NUMBER: 231103871 BUSINESS ADDRESS: STREET 1: 44370 OLD WARM SPRINGS BLVD. CITY: FREMONT STATE: CA ZIP: 94538 BUSINESS PHONE: 510-668-0881 MAIL ADDRESS: STREET 1: 44370 OLD WARM SPRINGS BLVD. CITY: FREMONT STATE: CA ZIP: 94538 FORMER COMPANY: FORMER CONFORMED NAME: American BriVision (Holding) Corp DATE OF NAME CHANGE: 20160111 FORMER COMPANY: FORMER CONFORMED NAME: METU BRANDS, INC. DATE OF NAME CHANGE: 20150908 FORMER COMPANY: FORMER CONFORMED NAME: ECOLOGY COATINGS, INC. DATE OF NAME CHANGE: 20080821 8-K 1 ea182176-8k_abvcbio.htm CURRENT REPORT
0001173313 false --12-31 0001173313 2023-07-24 2023-07-24 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

 

FORM 8-K

 

CURRENT REPORT

 

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): July 24, 2023

 

ABVC BIOPHARMA, INC.

(Exact name of registrant as specified in its charter)

 

Nevada   001-40700   26-0014658
(State or other jurisdiction
of incorporation)		   (Commission File Number)   (IRS Employer
Identification No.)

 

44370 Old Warm Springs Blvd.

Fremont, CA

   94538
(Address of principal executive offices)   (Zip Code)

 

Registrant’s telephone number including area code: (510) 668-0881

 

 

(Former name or former address, if changed since last report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of Each Class   Trading Symbol   Name of each exchange on which registered
Common Stock, par value $0.001 per share   ABVC   The Nasdaq Stock Market LLC

 

Indicate by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

 

Emerging growth company ☐

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

Item 2.02 Results of Operations and Financial Condition.

 

The information set forth under Item 2.02 is incorporated herein by reference.

 

Item 3.03. Material Modification to Rights of Security Holders.

 

ABVC BioPharma, Inc. (the “Company”) filed a Certificate of Amendment to its Articles of Incorporation (the “Certificate”) to be effective as of 12:01 a.m. EST on July 25, 2023 authorizing a 1-for-10 reverse stock split of the issued and outstanding shares of its common stock (the “Reverse Stock Split”). The Company’s stockholders previously approved the Reverse Stock Split at the Company’s Special Shareholder Meeting held on July 7, 2023.

 

Reason for the Reverse Stock Split

 

The Reverse Stock Split is being effected to reduce the number of issued and outstanding shares and to hope increase the per share trading value of the Company’s common stock, although that outcome is not guaranteed. In turn, the Company believes that the Reverse Stock Split will enable the Company to restore compliance with certain continued listing standards of NASDAQ Capital Market (“NASDAQ”).

 

Effects of the Reverse Stock Split

 

Effective Date; Symbol; CUSIP Number. The Reverse Stock Split will become effective at 12:01 a.m. Eastern Time on July 25, 2023, and will be reflected with NASDAQ and in the marketplace at the open of business on July 25, 2023 (the “Effective Date”), whereupon the shares of common stock began trading on a split-adjusted basis. In connection with the Reverse Stock Split, the Company’s shares of common stock will continue to trade on NASDAQ under the symbol “ABVC” but will trade under a new CUSIP Number: 00091F 304.

 

 Split Adjustment; No Fractional Shares. On the Effective Date, the total number of shares of the Company’s common stock held by each stockholder will be converted automatically into the number of whole shares of common stock, as applicable, equal to (i) the number of issued and outstanding shares held by such stockholder immediately prior to the Reverse Stock Split, divided by (ii) 10.

 

No fractional shares will be issued in connection with the Reverse Stock Split. Stockholders who otherwise would be entitled to receive fractional shares because they hold a number of common shares not evenly divisible by the one for ten reverse stock split ratio, will be entitled, upon surrender of certificate(s) representing these shares, to a number of common shares rounded up to the nearest whole number. The ownership of a fractional interest will not give the stockholder any voting, dividend or other rights except to have his or her fractional interest rounded up to the nearest whole number.

 

After the Effective Date, existing stock certificates will still be valid even though they reflect the number of shares prior to the Reverse Stock Split. If any stockholders seek to obtain a new certificate reflecting the number of shares post Reverse Stock Split, then such stockholders shall surrender to the exchange agent the certificates representing pre- Reverse Stock Split shares in exchange for certificates representing post- Reverse Stock Split shares in accordance with the procedures to be set forth in a cover letter asking for such stock certificates. The Company’s transfer agent, VStock Transfer, LLC charges stockholders a fee of $35 for each new certificate issued and $10 for cancelling each current certificate, plus mailing fees. A shareholder is not required to exchange their stock certificate.

 

1

 

 

Stockholders who are holding their shares in electronic form at brokerage firms or with the Company’s transfer agent (Vstock Transfer LLC) do not have to take any action as the effect of the Reverse Stock Split will automatically be reflected in their accounts.

 

State Filing. The Reverse Stock Split is being effected by the Company filing the Certificate with the Secretary of State of the State of Nevada on July 10, 2023. The Certificate is not effective until the Effective Date. A copy of the Certificate is attached hereto as Exhibit 3.1 and incorporated herein by reference.

 

Capitalization. The Reverse Stock Split did not impact the number of authorized shares of common stock.

 

As of July 24, 2023, there were 33,080,740 shares of common stock outstanding. As a result of the Reverse Stock Split, there will be approximately 3,308,074 shares of common stock outstanding (subject to adjustment due to the effect of providing cash for fractional shares). The Reverse Stock Split will not have any effect on the stated par value of the common stock.

 

Each stockholder’s percentage ownership interest in the Company and proportional voting power remains virtually unchanged as a result of the Reverse Stock Split, except for minor changes and adjustments that will result from rounding up fractional shares.

 

All options and warrants of the Company outstanding immediately prior to the Reverse Stock Split will be appropriately adjusted as a result of the Reverse Stock Split.

 

Item 5.03. Amendments to Articles of Incorporation or Bylaws.

 

The information required by this Item 5.03 is set forth in Item 3.03 above, which information is incorporated herein by reference.

 

Item 8.01 Other Events. 

 

On July 24, 2023, the Company issued a press release regarding the Reverse Stock Split. A copy of the press release is filed hereto as Exhibit 99.1 and is incorporated herein by reference.

 

Item 9.01 Financial Statements and Exhibits.

 

(d) Exhibits.

 

Exhibit
Number		   Exhibit
3.1   Certificate of Amendment to Articles of Incorporation
99.1   Press Release, dated July 21, 2023
104   Cover Page Interactive Data File (embedded within the Inline XBRL document)

 

2

 

 

SIGNATURE

 

Pursuant to the requirements of the Securities and Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  ABVC BioPharma, Inc.
     
July 24, 2023 By: /s/ Uttam Patil
    Uttam Patil
    Chief Executive Officer

 

 

3

 

 

 EX-3.1 2 ea182176ex3-1_abvcbio.htm CERTIFICATE OF AMENDMENT TO ARTICLES OF INCORPORATION

Exhibit 3.1

 

ARTICLES OF AMENDMENT

ABVC BIOPHARMA, INC.

 

1. This Article of Amendment (the “Article of Amendment”) amends the provisions of the Corporation’s Articles of Incorporation filed with the Secretary of State in November 2001 (the “Certificate of Incorporation”).

 

2. That the Board of Directors of the Corporation duly adopted resolutions through a unanimous written consent setting forth the following amendment (the “Amendment”) of the Articles of Incorporation of the Corporation, declaring said Amendment to be advisable and calling a meeting of the stockholders of said Corporation for consideration thereof.

 

3. That thereafter, pursuant to a resolution of its Board of Directors, a special meeting of the stockholders of said Corporation was duly called and held upon notice in accordance with Section 78.310 of Nevada’s Revised Statutes at which meeting the necessary number of shares as required by statute were voted in favor of this Amendment.

 

4. That the Articles of Incorporation of this Corporation be amended by adding the following paragraph to ARTICLE IV “Authorized Capital”:

 

“As of July 25, 2023, (the “Effective Time”), each ten (10) shares of Common Stock either issued and outstanding or held by the Corporation as treasury stock shall, automatically and without any action on the part of the respective holders thereof, be combined and converted into one (1) share of Common Stock (the “Reverse Stock Split”). No fractional shares shall be issued in connection with the Reverse Stock Split. All shares of Common Stock (including fractions thereof) issuable upon the Reverse Stock Split to a given holder shall be aggregated for purposes of determining whether the Reverse Stock Split would result in the issuance of a fractional share. If, after the aforementioned aggregation, the Reverse Stock Split would result in the issuance of a fraction of a share of Common Stock, the Corporation shall, in lieu of issuing any such fractional share, round up to the nearest whole number of shares in order to bring the number of shares held by such holder up to the next whole number of shares of Common Stock. No certificates representing fractional shares of Common Stock shall be issued in connection with the Reverse Stock Split. Each certificate that immediately prior to the Effective Time represented shares of Common Stock (“Old Certificates”) shall thereafter represent the number of shares of Common Stock into which the shares of Common Stock represented by the Old Certificate shall have been combined, subject to the elimination of fractional share interests as described above.”

 

[Remainder of the Page Intentionally Left Blank]

 

 

 EX-99.1 3 ea182176ex99-1_abvcbio.htm PRESS RELEASE, DATED JULY 21, 2023

Exhibit 99.1

 

 

ABVC BioPharma Announces Reverse Stock Split

 

 

Fremont, CA (July 24, 2023) – ABVC BioPharma, Inc. (NASDAQ: ABVC) (“Company”), a clinical-stage biopharmaceutical company developing therapeutic solutions in ophthalmology, neurology, and oncology/hematology, today announced a reverse stock split of its common stock (“Reverse Stock Split”) of one post-split share for every ten pre-split shares in an effort to regain compliance with Nasdaq’s listing rules. The Company expects the Reverse Stock Split to be effective as of 12:01 a.m. EST on July 25, 2023, authorizing a 1-for-10 reverse stock split of the issued and outstanding shares of its common stock under the new CUSIP Number: 00091F 304.

 

The Company obtained shareholder approval for the Reverse Stock Split at a special meeting of shareholders on July 07, 2023 and the Company’s board of directors approved the Reverse Stock Split ratio of 10 to 1. The principal purpose of the Reverse Stock Split is to decrease the total number of shares of common stock outstanding and hopefully, proportionately increase the market price of the common stock to meet the continued listing requirements of The Nasdaq Capital Market. The Company’s common stock will continue trading under the ticker symbol “ABVC.” The Reverse Stock Split will not impact the rights or preferences of the Company’s common stock shares. The ownership percentage and voting power of each stockholder will remain virtually unchanged. No fractional shares will be issued as a result of the Reverse Stock Split. Stockholders who would have received fractional shares due to their holdings not being evenly divisible by the reverse stock split ratio will receive shares rounded up to the nearest whole number.

The Company’s Board of Directors expressed that they aim for the Reverse Stock Split to not only enable the company to meet the NASDAQ listing requirements, but also to lead the company out of the ‘Penny Stock’ categoryThe Board further emphasized, “We believe this reverse stock split can have a positive impact on the Company’s market valuation, creating a solid foundation for growth. By improving our financial standing, we aim to instill confidence in our investors and attract a broader investor base. Ultimately, we strive to establish a more stable financial platform to attract investors and enable us to pursue our research and development activities with greater stability.”

 

The Company has appointed VStock Transfer, LLC as its exchange agent for the Reverse Stock Split. Stockholders owning pre-split shares via a bank, broker, or other nominee will have their positions automatically adjusted to reflect the Reverse Stock Split. They will not be required to take further action concerning the Reverse Stock Split, subject to brokers’ particular processes. Similarly, registered stockholders holding pre-split shares of the Company’s common stock electronically in book-entry form are also not required to take further action in connection with the Reverse Stock Split.

 

The company’s pipeline products have great market potential. As per the Future Market Insights report, the MDD market was valued at $11.51 billion in 2022 and is expected to reach $14.96 billion by 2032 with a CAGR of 2.8% over the forecast period1. According to the Polaris market research report, the global ADHD treatment market was valued at $16.13 billion in 2022 and is expected to reach $32.14 billion by 2030 with a CAGR of 7.1% over the forecast period2. According to iHealthcare Analyst, Inc., the global market for retinal surgery devices is expected to reach $4.3 billion by 2029, at a CAGR of 7.7%, driven in part by the rising geriatric population worldwide3.

 

1 https://www.futuremarketinsights.com/reports/major-depressive-disorder-treatment-market#:~:text=The%20major%20depressive%20disorder%20(MDD,US%24%2011.51%20billion%20in%202022
2 https://www.prnewswire.com/news-releases/global-attention-deficit-hyperactivity-disorder-adhd-market-size-projected-to-reach-usd-32-14-billion-by-2032--with-cagr-of-7-1-study-by-polaris-market-research-301729196.html#:~:text=According%20to%20the%20research%20report,Deficit%20Hyperactivity%20Disorder%20(ADHD)%3F
3 https://www.ihealthcareanalyst.com/technological-advancement-ophthalmic-surgery-retinal-surgery-devices-market/

 

 

 

 

About ABVC BioPharma

 

ABVC BioPharma is a clinical-stage biopharmaceutical company with an active pipeline of six drugs and one medical device (ABV-1701/Vitargus®) under development. For its drug products, the Company utilizes in-licensed technology from its network of world-renowned research institutions to conduct proof-of-concept trials through Phase II of clinical development. The Company’s network of research institutions includes Stanford University, the University of California at San Francisco, and Cedars-Sinai Medical Center. For Vitargus®, the Company intends to conduct global clinical trials through Phase III.

 

Forward-Looking Statements

 

This press release contains “forward-looking statements.” Such statements may be preceded by the words “intends,” “may,” “will,” “plans,” “expects,” “anticipates,” “projects,” “predicts,” “estimates,” “aims,” “believes,” “hopes,” “potential,” or similar words. Forward-looking statements are not guarantees of future performance, are based on certain assumptions, and are subject to various known and unknown risks and uncertainties, many of which are beyond the Company’s control, and cannot be predicted or quantified, and, consequently, actual results may differ materially from those expressed or implied by such forward-looking statements. None of the outcomes expressed herein are guaranteed. Such risks and uncertainties include, without limitation, risks and uncertainties associated with (i) our inability to manufacture our product candidates on a commercial scale on our own, or in collaboration with third parties; (ii) difficulties in obtaining financing on commercially reasonable terms; (iii) changes in the size and nature of our competition; (iv) loss of one or more key executives or scientists; and (v) difficulties in securing regulatory approval to proceed to the next level of the clinical trials or to market our product candidates. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company’s filings with the Securities and Exchange Commission (SEC), including the Company’s Annual Report on Form 10-K and its Quarterly Reports on Form 10-Q. Investors are urged to read these documents free of charge on the SEC’s website at http://www.sec.gov. The Company assumes no obligation to publicly update or revise its forward-looking statements as a result of new information, future events or otherwise.

 

This press release does not constitute an offer to sell, or the solicitation of an offer to buy any of the Company’s securities, nor shall such securities be offered or sold in the United States absent registration or an applicable exemption from registration, nor shall there be any offer, solicitation or sale of any of the Company’s securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of such state or jurisdiction.

 

Contact:

 

Tom Masterson

Email: tmasterson@allelecomms.com

 

 

 

 

 

 GRAPHIC 4 ex99-1_001.jpg GRAPHIC begin 644 ex99-1_001.jpg M_]C_X 02D9)1@ ! 0$ 8 !@ #_VP!# $! 0$! 0$! 0$! 0$! 0$! 0$! M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_ MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P 1" Q &@# 2( A$! Q$!_\0 M'P 04! 0$! 0$ $" P0%!@<("0H+_\0 M1 @$# P($ P4% M! 0 %] 0(# 01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D* M%A<8&1HE)B7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7& MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$ P$! 0$! M 0$! 0 $" P0%!@<("0H+_\0 M1$ @$"! 0#! <%! 0 0)W $" M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$ MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4 MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,! (1 Q$ /P#^_BBBO@G_ M (*(_M^_"K_@GK\!=5^*_CN2#6_&.K"ZT;X4?#:&\2#5_'_C#[,9(+1 -TUI MX?TH-'?>)M:\IHM,T\!%\R_N[&VN #R'_@J%_P %.O"'_!/OP#H&D^&M#LOB MI^TU\4KRVTGX.?!B.:\DFU6>YOHK!O$/B2'2-^K6WAV&ZE33[*&S5-1\0ZS- M#I6E(/@A\.M>\0:(+'X4>&+J(GP_XA&@ MW%_)'HNHV^E31V?@+02HD\*Z.QUBY1O$NI&YLZ'_ ;2.LL/_!2*57619?VJ M[>5958.LJR0^+W65)%)61)%8.LBEE=6#J2""0# \-_\ !9;_ (*F?&GXI_'_ M ,$?LO?L%_"GXU:#\"?BCK_P^US5]*UGQG%=V*6NM:U8^'I-96Y\2Z? M_J] MAHUQ=LEDC0AHI]H1%45Z'+_P41_X+WQ122'_ ()/^!V$:.Y6/6O%$LC!%+$1 MQ)XTWR.<86-/F=L*O)%?F-^P#\;?^"BOP@_: _X**1?L(?LS>"_VA--U[]I7 M5YOB9=^+=5DTQ_"NIV/B+QY%X9M+ IK^A^,-^H%Y^ MVO\ \'"D5I=2K_P3<^$*M';3NK6_B.YO+A66)BK06B^/MUU,I :.W&#.X$0. M6H^0'T5^S9_P5B^+7[7?[+/[2VL_"3X%Z%X3_;G_ &6[&:Y\;_LX_$2X\0OH M.OR:=)=R7L7A^ZL)-*\26]U?QZ1K>DVNEWT4E[I7B6WL-/O&OK;4[6[?W3_@ MDI_P4PLO^"D'P5\3>(O$WA[P_P" /C;\-?$DFA?$GX?>'[R_N--L[#43-<>% M?$FCC6)9-5.EZO:P7=CE:E:M)L$.?RW_P"#>*\G\?\ [0/_ 40 M^,/QPU;5++]LGQ+X]TNT^*GP_P!3T >&?^$G63/7@7[5>BZW_P11_X*S>#OVLO ^GW=M^R1^UC?ZG;_ M !'T+3(I1I6E?VUJ-K%5A2[\.:O/8_%#PE;!3NMY=1TNU\Q(IXHP M#^R6OP=\;_\ !6#XQ>./^"H&A?\ !/K]D7X7?#3XB>'?#=S#:?'/XJ^,+[Q1 M(/!DFBL=0^(LVD0>'[ZQL)(/"&FR6F@K_:$DAO\ QK=KI,3!8]DGT[_P5$_X M*">%OV,?V*-<^-G@_7M)U?QQ\4=(MO#?[/OV:ZAN+?7?$/BW2#>Z=XOM K'[ M5H?AC0YF\5W-RJO;N(=/M)#OU&!9/S"_X)0?L:^._P!EW_@G%^TO^V+XEL]1 MNOVI_P!I/X-?$7XAZ-J&J+.?$V@^#(?#&NZ_X0B>:3R[J+6/%>JS2>/=5PPD MFEN=#1B)+,1( >]?M6_\%OM5T+X[:]^RM_P3^_9M\1?MG_&SPG/0_P#!>O\ Z1+>%_\ P-\7#_W=*]7_ .#:GP/\,]._8!F^)7AR/3]1^)_Q M#^*OC8_%KQ(ZQS>(9-3T6YM8M#T+4;QA]I%G::/W9WR3$K M_0W0!\P?L;_$GX^?%S]G?P%X_P#VG/A):_ SXU:XNN'QA\,;)[R2V\.-9:_J M5CI(C>_O=1NC_:&CVUCJ3>;=RX:[(7:N%!7T_10!SWBW6-3\/^&/$&N:+X;U M+QCK&DZ1J%_I?A/1[G3;+5/$>H6MM)+9Z+8WFLW=AI5I&Q7_;OBWQ'<7FJ7SVME:6<, MO[3_ /!2G]HOXX_LP?LZ1_$O]GWP?9^-_'K>/?#'AXZ+>^%M>\7PC1=534FU M&[_LGP[=V>H;X&M;=5NC-Y$'F'S5;)P7+FO$6 RO%^VPGL?:OZKB4ZGLG[>'LZ MOPU+3Y?A9^-\=>.?!7AYGO\ J]G^%XLK8_ZEA,?SY+PMF6<8+V&,]LZ*^N82 M2I>V7L)^UHVYJ=X&M4U(6-U) ]@]Q!J"VES)--(X@ 5@OP#_ ,/F?^"IW_1M M_A[_ ,,-\6/_ )?U:L_^"RO_ 5)FE9)?V*O!/C+@[AS..*,WQ/"U3+,CP%[:2P'B#KWX!SM+_THR?@'\!?^"W7[#OQE_:ZU M[]FO]E#X8>+?"G[0OQLUSQU)J7C_ ,>> [F:73M/UWQ0_AJZTN&T^(>BW5C% M?:9K[SW5K?Q-.)/)#QPO&RU]6R_M$?\ !R>\4B1?L5?LW0R/&ZQS?\)=X3E\ MIV4A9?*;XOJLGEL0WELP#XVDC.1\]?\ #XO_ (*@_P#1N?A[_P ,5\6?_EW1 M_P /B_\ @J#_ -&Y^'O_ Q7Q9_^7=?SU_K=E7_/O,O_ W5_P#,T_XFH\,? M^@'C_P#\0/.__DC](O\ @D9_P3^^/O[.?BG]HO\ :P_;#UO0M0_:C_:JUZ/4 M_%6A>&;NTOM*\(:,NHW.LW-I=7VF_P#$HN=6U;5)K:22UTF2[T[1].TK3K.# M4+R>6\D'V=_P4B_8O\/_ +=_[)OQ&^!M_'96_B^2S/BGX5>(+J.//ASXEZ!! M<3^'+OSWP8+'4GDGT#62'"OH^JWN]9-JK7XN_#C_ (*Q?\%'_$QU@>(/@%H5 ME]B%G]E\OX+?$^T\TS_:/-S]IUEO,V>6F-F-N[YNHKT__AYQ^WY_T1#1_P#P MT7Q%_P#EO7AXSQ.X:P.(J86M1SUU:7+S.ED>-JT_?A&:Y9Q?++W9*]MG==#O MH_27\.:].-6&#XY49WLI\$YQ"6DG%WBW=:IV[K4_-G]G/_@D7_P4L^/_ ,7_ M -D/X:_M]>$SHG[)W[+-C?VFG6]QX^\#>(S-X6L=5'B%/ \-EX<\0:IJFHS^ M*-1@T_P^VLWUH#IW@ZT33&D%O9VEL/[65TO35TP:*NGV0T=; :6-*^S0_P!G M#31;_9!I_P!CV?9_L0M?]&^S>7Y/D?NMFSY:_G,_X>$6,Q2JYEC;X>E5E1:6'I2]ZO5O2A[QQYI]*3PSRC!S MQV+P7'LJ%.=*G)8;@7.\15YJT_9PM2IOF:YOB:TBM7H>=>+?^";7O%7[-'Q%U#3K:T\.ZE)/-I6>G-\9_&KPK:^$?%.G^/M7\.V6 MFVGAW6O#,C:!>VMX;#7;BXNY7DN]1OHC=1N+>00K&BAXI"2OQS/LEQG M#F5Y_@*>8X&GFF!K99F$,/4JXFE%8S+\3^_PE;GPM7F MHU??C%TY/2I$];_:H^/VE?LL_L\_%?\ :$UOPYJ7B[2OA5X6F\3WGAK2+VQT MW4M9CBN[2S6RM-0U-ET^SD>2[1C? MKQ9\"+SXUETA9/L6K:K:1V$^I ZW$ZE?K_\ :S_9_MOVJ/V>*+CP7;?% M;PI-X8E\56ND6NOSZ)YEY9WJWJZ+?7%I9ZH%>S5)+*YN(H9XW=';:2#\+_"S M_@E]K'A#XS?!WXL^-?CGX,UJ#X+>)+KQ=H.@_"7]EGX1?L^:GKNL2^'=4\.0 M6/BOQIX!FEUW6?"8MM5ENM2\*W"G3M9N[>RENV5[2)AY!]$?:7A?]IG2O$W[ M6?QC_937PGJ-AJ?P?^#?PD^,-]XXGU2R?2-:L?BOKWQ!T.VT2VTM8EO;*ZT) MO %Q=7E[<3O;746IP) D;6\I;Y8N?^"E=TOA#5OCWI_[+OQ9U3]CW0_$&HZ7 MJ/[1L&O>"H96\,Z+K-QXNZQJDE]\%$^'/A2Y\=6_@/7M>N/$.O?"#3/C/<7K:I:^ M3O+V^ MLA+/X9N_$MGX=N7\/6VLBUVS( >U?M5_MLV'[-VK?!/0M%^']O\ $W4?CC#X MQO?#MU<_%'P!\*O#=CIG@W1M(UNZO;OQ5\0[[3]$EDU*UUFU&EV,-R+N[VRO M%&ZQOMQ]%_X*"_#_ %K]C&3]LY/!OB&Q\)Z?XAA\+:WX8OM5T 7.GZK#\5[+ MX1ZW=6?BFUN[KPOK?AK3=;N9]5M/%&F7LND:UH5K]NLI@LZ!?6_BA^R?\./B MQ\3?@)XY\6:;H&L>&O@-H7Q%T/2OAMXB\):-XH\,:U'X[T/P]H5G&]+N='L=*\(>-?#OC Z)#X:S8Z4=,U5= .D7%J%C@BM;Z:189"@B< H>% M?VK_ (8^//VC)?V>/ NK:)XUOK;X*S?&:]\9^$O%?A[Q'X>L;2+QS:^"!X8O M$T>\O)[?699KN/58VE=(FL00%+D$\'XP_;I^&?@W]L3P1^Q[?:%XDN==\7:% M9SZA\2+9+<^ O!WCGQ#8:_K7@+X7^)+QV$]MXR\?^'O"OB+7/#EHBLD]K81( MQ\R\A Z7P+^QS\*?A=^TG M8LOA MEX>TZP\(Z8-6LY+G4]+%_+=SQ3:A((P#Z(_:U_;-'[,'BWX0>!['X:)\0_$/ MQ@M_'MYIAU#XI?#[X3:)I%MX M?#]SJ'V[Q%\1;_ $[29[N_'B&W33["VN#= MS&WN&6-E0D>>>)_^"D_@#P]^P/>_M[P_#3QSK'A/2YHK&_\ AU87.BS>*I-4 MB^(\?PRU2UT/5;6YO/#_ (CL[?6_M%WI&KZ/=W.G^(]-C@N--E_TN-4]8_:. M_8G^%_[5WB'X?WWQOM]-\9^%O"'PY^+?P_UGP;J7AW3[JQ\0M\6=+\+:;>>) M+"^NI)[CPOKGAUO#9O-"O=-BEN[:XOBT5U";=6EYO7/V+=2\6_L=>%/V2_%O MQ@O=8'@_5/AI)I_Q+A\#Z'I6JW^A_"GXB>'?&WAG3M5\,Z?>PZ)+J,^F^&K# MPYK.KVK6PU%VN-=>Q6\N)8& ,#Q'_P %)/@G8?%?]C/X3^$K#6O'^I?MFZ7' MXF\+ZQH,EK'IG@/P;>Z+=ZGHOB/QF9\R6XUS4=/U'P_IVEQ%;Z34]*U9"H&F MW 7M_P!L']N/X=?L<2_"BV\9>&_%/BZZ^)GBLV%_;>$((;N?P#\.=(FTZ+QW M\8O%<3L9;?P-X"&LZ*=;N8TWLVIP1QR(P8CR3PA_P2Y^"'PV^(FF_$;XP_:'N;35WMO$5I9:9IFA^/M/T[X,^"Q-]A;P9\,].UGXB^(O$^G MZ7:?;FMM5NYV(E$JM%T_QM_X)R?"7]I?XT>/?BU\>O$_CWQ?9>(?A;9?!KP5 MX(\-^+/%/PYTCP)X"O5O;KQ_ILUWX/\ $6GS^,)/B'K-U:W^M+KL'V"*TTC2 M]-^PW45L)J /T'AFAN88KBWEBGMYXHYH)X9%EAFAE4/%+%*A9)(I$97CD1F5 MU8,I((-%>0?L^_"_6/@I\%_AU\)-<\=ZG\3+OX=>&K+PC;>-]:T^WTS6= EX-101.SCH 5 abvc-20230724.xsd XBRL SCHEMA FILE 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 6 abvc-20230724_lab.xml XBRL LABEL FILE Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] EX-101.PRE 7 abvc-20230724_pre.xml XBRL PRESENTATION FILE XML 8 R1.htm IDEA: XBRL DOCUMENT v3.23.2
Cover
Jul. 24, 2023
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Jul. 24, 2023
Current Fiscal Year End Date --12-31
Entity File Number 001-40700
Entity Registrant Name ABVC BIOPHARMA, INC.
Entity Central Index Key 0001173313
Entity Tax Identification Number 26-0014658
Entity Incorporation, State or Country Code NV
Entity Address, Address Line One 44370 Old Warm Springs Blvd.
Entity Address, City or Town Fremont
Entity Address, State or Province CA
Entity Address, Postal Zip Code 94538
City Area Code 510
Local Phone Number 668-0881
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock, par value $0.001 per share
Trading Symbol ABVC
Security Exchange Name NASDAQ
Entity Emerging Growth Company false
XML 9 ea182176-8k_abvcbio_htm.xml IDEA: XBRL DOCUMENT 0001173313 2023-07-24 2023-07-24 iso4217:USD shares iso4217:USD shares 0001173313 false --12-31 8-K 2023-07-24 ABVC BIOPHARMA, INC. NV 001-40700 26-0014658 44370 Old Warm Springs Blvd. Fremont CA 94538 510 668-0881 false false false false Common Stock, par value $0.001 per share ABVC NASDAQ false EXCEL 10 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 11 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 12 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 13 FilingSummary.xml IDEA: XBRL DOCUMENT 3.23.2 html 1 23 1 false 0 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://abvcpharma.com/role/Cover Cover Cover 1 false false All Reports Book All Reports ea182176-8k_abvcbio.htm abvc-20230724.xsd abvc-20230724_lab.xml abvc-20230724_pre.xml ea182176ex3-1_abvcbio.htm ea182176ex99-1_abvcbio.htm http://xbrl.sec.gov/dei/2023 true false JSON 15 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "ea182176-8k_abvcbio.htm": { "axisCustom": 0, "axisStandard": 0, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2023": 23 }, "contextCount": 1, "dts": { "inline": { "local": [ "ea182176-8k_abvcbio.htm" ] }, "labelLink": { "local": [ "abvc-20230724_lab.xml" ] }, "presentationLink": { "local": [ "abvc-20230724_pre.xml" ] }, "schema": { "local": [ "abvc-20230724.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd" ] } }, "elementCount": 59, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2023": 3, "total": 3 }, "keyCustom": 0, "keyStandard": 23, "memberCustom": 0, "memberStandard": 0, "nsprefix": "ABVC", "nsuri": "http://abvcpharma.com/20230724", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "span", "p", "body", "html" ], "baseRef": "ea182176-8k_abvcbio.htm", "contextRef": "AsOf2023-07-24", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "00000001 - Document - Cover", "menuCat": "Cover", "order": "1", "role": "http://abvcpharma.com/role/Cover", "shortName": "Cover", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "span", "p", "body", "html" ], "baseRef": "ea182176-8k_abvcbio.htm", "contextRef": "AsOf2023-07-24", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description of changes contained within amended document.", "label": "Amendment Description" } } }, "localname": "AmendmentDescription", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://abvcpharma.com/role/Cover" ], "xbrltype": "stringItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://abvcpharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AnnualInformationForm": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.", "label": "Annual Information Form" } } }, "localname": "AnnualInformationForm", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://abvcpharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AuditedAnnualFinancialStatements": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.", "label": "Audited Annual Financial Statements" } } }, "localname": "AuditedAnnualFinancialStatements", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://abvcpharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://abvcpharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CountryRegion": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Region code of country", "label": "Country Region" } } }, "localname": "CountryRegion", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://abvcpharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2023", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://abvcpharma.com/role/Cover" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentAccountingStandard": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.", "label": "Document Accounting Standard" } } }, "localname": "DocumentAccountingStandard", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://abvcpharma.com/role/Cover" ], "xbrltype": "accountingStandardItemType" }, "dei_DocumentAnnualReport": { "auth_ref": [ "r11", "r13", "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an annual report.", "label": "Document Annual Report" } } }, "localname": "DocumentAnnualReport", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://abvcpharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://abvcpharma.com/role/Cover" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://abvcpharma.com/role/Cover" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://abvcpharma.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentPeriodStartDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format.", "label": "Document Period Start Date" } } }, "localname": "DocumentPeriodStartDate", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://abvcpharma.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r12" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://abvcpharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentRegistrationStatement": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a registration statement.", "label": "Document Registration Statement" } } }, "localname": "DocumentRegistrationStatement", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://abvcpharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentShellCompanyEventDate": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Date of event requiring a shell company report.", "label": "Document Shell Company Event Date" } } }, "localname": "DocumentShellCompanyEventDate", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://abvcpharma.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentShellCompanyReport": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.", "label": "Document Shell Company Report" } } }, "localname": "DocumentShellCompanyReport", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://abvcpharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r15" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://abvcpharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://abvcpharma.com/role/Cover" ], "xbrltype": "submissionTypeItemType" }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Documents incorporated by reference.", "label": "Documents Incorporated by Reference [Text Block]" } } }, "localname": "DocumentsIncorporatedByReferenceTextBlock", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://abvcpharma.com/role/Cover" ], "xbrltype": "textBlockItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://abvcpharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://abvcpharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine3": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 3 such as an Office Park", "label": "Entity Address, Address Line Three" } } }, "localname": "EntityAddressAddressLine3", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://abvcpharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://abvcpharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCountry": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ISO 3166-1 alpha-2 country code.", "label": "Entity Address, Country" } } }, "localname": "EntityAddressCountry", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://abvcpharma.com/role/Cover" ], "xbrltype": "countryCodeItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://abvcpharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://abvcpharma.com/role/Cover" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.", "label": "Entity Bankruptcy Proceedings, Reporting Current" } } }, "localname": "EntityBankruptcyProceedingsReportingCurrent", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://abvcpharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://abvcpharma.com/role/Cover" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://abvcpharma.com/role/Cover" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://abvcpharma.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://abvcpharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r19" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Elected Not To Use the Extended Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://abvcpharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://abvcpharma.com/role/Cover" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://abvcpharma.com/role/Cover" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://abvcpharma.com/role/Cover" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r16" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://abvcpharma.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityPrimarySicNumber": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.", "label": "Entity Primary SIC Number" } } }, "localname": "EntityPrimarySicNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://abvcpharma.com/role/Cover" ], "xbrltype": "sicNumberItemType" }, "dei_EntityPublicFloat": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.", "label": "Entity Public Float" } } }, "localname": "EntityPublicFloat", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://abvcpharma.com/role/Cover" ], "xbrltype": "monetaryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://abvcpharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://abvcpharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://abvcpharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://abvcpharma.com/role/Cover" ], "xbrltype": "employerIdItemType" }, "dei_EntityVoluntaryFilers": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.", "label": "Entity Voluntary Filers" } } }, "localname": "EntityVoluntaryFilers", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://abvcpharma.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityWellKnownSeasonedIssuer": { "auth_ref": [ "r17" ], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.", "label": "Entity Well-known Seasoned Issuer" } } }, "localname": "EntityWellKnownSeasonedIssuer", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://abvcpharma.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_Extension": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Extension number for local phone number.", "label": "Extension" } } }, "localname": "Extension", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://abvcpharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://abvcpharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_NoTradingSymbolFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a security having no trading symbol.", "label": "No Trading Symbol Flag" } } }, "localname": "NoTradingSymbolFlag", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://abvcpharma.com/role/Cover" ], "xbrltype": "trueItemType" }, "dei_OtherReportingStandardItemNumber": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.", "label": "Other Reporting Standard Item Number" } } }, "localname": "OtherReportingStandardItemNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://abvcpharma.com/role/Cover" ], "xbrltype": "otherReportingStandardItemNumberItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r7" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://abvcpharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r8" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://abvcpharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://abvcpharma.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_Security12gTitle": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(g) registered security.", "label": "Title of 12(g) Security" } } }, "localname": "Security12gTitle", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://abvcpharma.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://abvcpharma.com/role/Cover" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SecurityReportingObligation": { "auth_ref": [ "r9" ], "lang": { "en-us": { "role": { "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.", "label": "Security Reporting Obligation" } } }, "localname": "SecurityReportingObligation", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://abvcpharma.com/role/Cover" ], "xbrltype": "securityReportingObligationItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r10" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://abvcpharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://abvcpharma.com/role/Cover" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r18" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://abvcpharma.com/role/Cover" ], "xbrltype": "booleanItemType" } }, "unitCount": 3 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r10": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r11": { "Name": "Form 10-K", "Number": "249", "Publisher": "SEC", "Section": "310", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r12": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r13": { "Name": "Form 20-F", "Number": "249", "Publisher": "SEC", "Section": "220", "Subsection": "f", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r14": { "Name": "Form 40-F", "Number": "249", "Publisher": "SEC", "Section": "240", "Subsection": "f", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r15": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r16": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r17": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "405", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r18": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r19": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-23", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r5": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "g", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r6": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12, 13, 15d", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r7": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r8": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r9": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "15", "Subsection": "d", "role": "http://www.xbrl.org/2003/role/presentationRef" } }, "version": "2.2" } ZIP 16 0001213900-23-059044-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001213900-23-059044-xbrl.zip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